Beware of Trademark Scams

Many trademark applicants are getting official looking notices from scam artists. These notices make it appear that the notice is from the United States Patent and Trademark Office. Unless carefully examined these notices can fool just about anyone.Continue reading

Find high quality clinical research sites in Arizona with ASU CONECTR

 

ASU CONECTR, an established network of high quality clinical research sites in Arizona, assists organizations in the placement and conduct of clinical trials.  Committed to excellence in clinical research processes, CONECTR sites have a track record of rapid study start-up, faster contract and regulatory turnaround times, and successful patient enrollment.   For more information about CONECTR, go to www.conectr.org .Continue reading

The Next Steps After SBIR/STTR Reauthorization

This year, technology and business organizations, including AZBio worked together with Congress to reauthorize the Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) program. Sean Greene, Associate Administrator for Investment and Special Advisor for Innovation at the U.S. Small Business Administration, has recently shared his thoughts on what comes next on the SBA Community Blog…Continue reading

From Discovery to Patient: The Journey of a New Drug

The development of a new drug is a long, complicated process involving up to 15 years of research and, in many cases, hundreds of millions of dollars. There are two distinct processes that every drug must go through before reaching the general patient population and treating a specific disease – Drug Discovery and Drug Development.Continue reading

Making Sense of the Medical Device Tax

Estimated at $20B, the Medial Device Tax was included in the Affordable Care Act that was signed into law by President Obama in 2010. The amount is based on a 2.3% excise tax that will be levied on the total revenues of a company, regardless of whether a company generates a profit, starting in 2013.

While many industry groups including AZBio, AdvaMed, and MDMA have been sharing information on why this tax is unwise and have worked to explain the negative effects that it could have on innovation and patient care, there is always the possibility that it will not be repealed before 2013.

Ernst and Young recently published a Tax Note on the Medical Device Tax that gives a comprehensive overview of what it is, who it affects and how they will be affected.  The tax note is provided below as published by E&Y and is shared with permission.Continue reading